(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

This is also true for intrinsic restrictive lung diseases like pneumonia. Other conditions can be harder to treat. For example, until recently, there was little that could be done to treat idiopathic ...

Patients were excluded if they had any of the following: known congenital lung disease; mental or cognitive impairment; use ...

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

Liver fibrosis is a progressive and potentially reversible condition that results from chronic liver damage, which can be ...

There is less distortion of cell structure and less cell loss (especially the selective loss of lymphocytes) when the original sample (before centrifugation and resuspension) is used for the ...

Group 1 PH is due to pulmonary arterial hypertension (PAH), a condition in which the tiny arteries in your lung become ...

Long-term changes in cardiac structure/function in patients with COPD varied by lung structure, with greater baseline WA linked to greater RV mass.

Endothelin (ET) is a recently discovered 21-amino acid peptide that has potent physiologic and pathophysiologic effects that appear to be involved in the development of heart failure. These ...